Renal Pseudotumour Following Treatment of Wilms’ Tumour

fol&tt il1etab0lic

Esche:t~chia colij and sulfam stb_oxazo12 it I-1as been unu_s1_1al for resi2tance to both antimicrobial agents to en1erge. to mutation is w.,,.i.,vo,y 1

trirr1ethor on aeroo1,cauv grov;,n fecal bacteria was monitored in 136 students from the United States during a 2-week diarrhea n"'"''"'"''""n 1n Iviexico. Unlike µa.en"-"""' in other studies with these agents who tract infection or b~-.,--,•()(_;:_,:rrr,rnsn, most n;,,n1,mrn in total fecal Enterobacteriaceae and sulfamethoxazole resistuu,,a,c~,,w,x,u,ene

isolated_ Of 165 CU.iUCC!RO}JJCLUC,' resistant E. coli isolates 96 per cent were resistant to at least 4 antimicrobial agents and 25 per cent were resistant to 7. Tri· methopri.J.11 resistance was transferable in 40 of 100 strains tested. Despite the hick of -'-"''"'"''''-"-'resistance in other studies of the authors believe that their results dearly demonstrate the rernarkable ua''°"·''"Y for emergence an
tract process that includes transition frorn normal a~,,,n,-,~,.,·.= to epitheca:rcino-rr_~a in situ and invasive carcinon1.a. The incidence urothelial changes of the renal µa.u,,w,,, with analgesic PnhYnn,at_l,rn the of whom n,mlhr,P>t'tomv before or after renal transplantation. was noted in 27 of the 56 patients, bilaterally was detected in any from patients with chronic n"·,,,,,.mc>r1m·vr, chronic glomerulonephritis or chronirejected allografts. Patients with end stage analgesic nehnr1n«t111v are at high risk for developing tract tumors should be to regular endoscopic

Editorial comment. There are increasing reports on the occurrence of urina1·y tract neoplasms in association with analgesic abuse_ This analgesic abuse centers primarily on phenacetin. The occurrence of these tumors in relation to analgesic abuse has not been extremely common in the United States. However, in my opinion, it increasingly becomes apparent that we do not '"'"'"'"""' our patients and extensively about the abuse of analgesics when they are being evaluated. I truly wonder if some of my patients with urothelial neoplasms or other variants, or premalignant ueuµaa"11"" may not actually be .,aa,,~,.,_au who abuse the use of analgesics. Possibly, some of the other abnormalities of the VH'OH~"'", such as Ieukoplakia and ri-'-•"-U''-"-"«'H", may not be the result of analgesic abuse. A T. E. Renal Pseudotumour Follffwing Treat1¥1ent of Wilms' Tu.mour

Res. Comm. Chem. Path. Pharm., 35: 17--26

K

1982

Ein Kerem Je-

Mean residence time was determined on the arterial and

J_ The rnear;. residence tlJ11e values calculated f1on1 fe1noral venous data •Nere '"'---,-,,.,.._0 fro1n 1.5 to 109 per cent) than_ those from femoral_ artHia-1 data. With conventional rnethods the mean residence time calculated from the mterial blood represents the true me2.11 residB11ce thne in the The authors propose nevv that eJir:ninate the effect of -2oncentcation differences rnean rem."' avoid dence P. 29 references

ONCOLOGY AND CHEMOTHERAPY Renal Pelvic e,ml tient§ With End-Stage .n.,.,a.,;,;,,m,., I.

BLOHME AND s. JOHANSSON, Departments Pathology, Sahlgren's Hospital, University Goteborg, Sweden

E. and

ABU-DALU AND

19: 9-13 (Jan.) 1982

These authors have indicated the dramatic i,-nprovement of survival of,,~-"""""~ with combinations of surgery, radiotherapy report an unusual case after right nephxe,::tc,my r,,r1, 1-·hc•r""" and for Wilms tumor 0

not8d an enlargement of the lower

of the contralateral

and fyozen and permanent sectio:::1.s with fibrosis. Tb.ese authors att1~ibute these to the cross-field ra,11
N. J. 6 figures, 9 references

and

of Goteborg,

Kidney Int., 20: 671-675 (Nov.) 1981 More than 100 cases have been reported of renal pelvic tumors in patients who abuse phenacetin-containing analgesics. Recently, tumors of the bladder and ureter also have been reported in phenacetin abusers. Tumor development in

Cell Surface Antigen-A Study in Bladder Tumours J. N. KULKARNI, M. R. KAMAT, S. G. GANGAL AND G. V. TALWALKAR, G. U. Service, Tata Memorial Hospital, and Immunology Division, Cancer Research Institute, Parel, Bombay, India

J. Surg. OncoL, 19: 14-17 (Jan.) 1982